Remus Pharmaceuticals Approves Main Board Migration and New Dominican Republic Subsidiary
Remus Pharmaceuticals Ltd 路 Outcome 路 03 Sept 2026, 12:01 am
Remus Pharmaceuticals Approves Main Board Migration and New Dominican Republic Subsidiary On 2nd Sep'26, Remus Pharmaceuticals approved the migration of its shares from the NSE Emerge platform to the NSE and BSE Main Boards, pending shareholder and regulatory approvals. The Board also authorized forming a pharmaceutical supply and distribution subsidiary in the Dominican Republic, with Remus acquiring a 51% or greater equity stake via cash consideration. Additionally, experienced FMCG entrepreneur Ashutosh Naginbhai Valani was appointed as a Non-Executive Independent Director for a five-year term, effective immediately.
Original exchange filing (PDF)
More announcements from Remus Pharmaceuticals Ltd
- Remus Pharmaceuticals Limited has informed the Exchange about Transcript 路 06 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Audio Recording 路 04 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Investor Presentation 路 04 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange regarding a media release dated November 03, 2026 路 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Interim Dividend is 07-Nov-2026. 路 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on November 03, 2026, declared Interim Dividend of Rs. 1.00 per equity share. 路 03 Nov 2026
- Remus Pharmaceuticals Limited has submitted to the Exchange Outcome of Board Meeting held on November 03, 2026 路 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Schedule of meet 路 29 Oct 2026
